Buscar resultados de ensayos clínicos
Childhood Hepatocellular Carcinoma - 12 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Condición:
|
Recruiting |
Nombre del estudio: Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Condición:
|
Active, not recruiting |
Nombre del estudio: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Condición:
|
Completed |
Nombre del estudio: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Condición:
Intervenciones: |
Completed |
Nombre del estudio: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Condición:
Fecha: 2004-09-07 Intervenciones: Drug: oxaliplatin Given IV Other Names: |
Withdrawn |
Nombre del estudio: Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer Condición: Liver Cancer Fecha: 2009-05-09 Intervenciones:
|
Withdrawn |
Nombre del estudio: Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery Condición: Liver Cancer Fecha: 2007-05-08 Intervenciones:
|
Withdrawn |
Nombre del estudio: Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Condición: Liver Cancer Fecha: 2006-01-12 Intervenciones:
|
Recruiting |
Nombre del estudio: Collecting and Storing Tissue From Young Patients With Cancer Condición: Cancer Fecha: 2009-05-09 Intervenciones:
|
Completed |
Nombre del estudio: Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Condición: Cancer Fecha: 2005-09-08 Intervenciones: Biological: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/k |